For ccRCC patients, particularly those classified as high-risk based on their Ki-67 index, close postoperative monitoring, adjunctive immunotherapy and targeted therapy are recommended [15, 16]. The gene discussed is MKI67; the disease is nonpapillary renal cell carcinoma.